Literature DB >> 31866468

Grading of Recommendations Assessment, Development, and Evaluations (GRADE) notes: extremely serious, GRADE's terminology for rating down by three levels.

Thomas Piggott1, Rebecca L Morgan1, Carlos A Cuello-Garcia2, Nancy Santesso1, Reem A Mustafa3, Joerg J Meerpohl4, Holger J Schünemann5.   

Abstract

OBJECTIVES: The Grading of Recommendations Assessment, Development, and Evaluations (GRADE) system for assessing certainty in a body of evidence currently uses two levels, serious and very serious, for downgrading on a single domain. In the context of newer risk of bias instruments, such as Risk of Bias in Non-Randomized Studies I (ROBINS-I), evidence generated by nonrandomized studies may justify rating down by more than two levels on a single domain. Given the importance users of GRADE assign to terminology, our objective was to assess what term GRADE stakeholders would prefer for rating down certainty by three levels. STUDY DESIGN AND
SETTING: We conducted a purposefully sampled online survey of GRADE stakeholders to assess possible terms including "critically serious," "extremely serious," "most serious," and "very, very serious" and conducted a descriptive and thematic analysis of responses. We then facilitated a GRADE working group workshop to generate consensus.
RESULTS: A total of 225 respondents ranked and rated "extremely serious" highest, closely followed by "critically serious." Respondents felt that "extremely serious" was "more understandable" and "easiest to interpret". GRADE working group members described that the terms "extremely serious" appeared clearer and easier to translate in other languages.
CONCLUSION: Based on this stakeholder-driven study, "extremely serious" is the preferred term to rate down certainty of evidence by three levels in the GRADE approach.
Copyright © 2020 Elsevier Inc. All rights reserved.

Keywords:  Certainty of evidence; Evidence-based medicine; GRADE; Guidelines; Levels of evidence; Quality of evidence; Risk of bias; Systematic reviews

Year:  2019        PMID: 31866468     DOI: 10.1016/j.jclinepi.2019.11.019

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  6 in total

1.  A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.

Authors:  Yu Hong; Wenbo Huang; Daiyin Cao; Jilai Xu; Huifan Wei; Jie Zhang; Li Wang
Journal:  Psychopharmacology (Berl)       Date:  2022-09-05       Impact factor: 4.415

2.  The effectiveness and safety of Chinese herbal formulas on skin photoaging: A protocol for systematic review and meta-analysis.

Authors:  Ji-Yong He; Xiao-Yv Yv; Jing-Dong Wu; Ling Lv; Xiao-Qing Zhang; Tie-Ming Ma; Yu Zhang
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

3.  A systematic review and meta-analysis on correlation of weather with COVID-19.

Authors:  Poulami Majumder; Partha Pratim Ray
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

Review 4.  Control of Allergic Rhinitis and Asthma Test: A systematic review of measurement properties and COSMIN analysis.

Authors:  Rafael José Vieira; Bernardo Sousa-Pinto; António Cardoso-Fernandes; Cristina Jácome; Diana Portela; Rita Amaral; Ana Sá-Sousa; Ana Margarida Pereira; Jean Bousquet; João Almeida Fonseca
Journal:  Clin Transl Allergy       Date:  2022-09       Impact factor: 5.657

5.  Prevalence of hypertension in Ghanaian society: a systematic review, meta-analysis, and GRADE assessment.

Authors:  Fidelis Atibila; Gill Ten Hoor; Emmanuel Timmy Donkoh; Abdul Iddrisu Wahab; Gerjo Kok
Journal:  Syst Rev       Date:  2021-08-07

Review 6.  Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review.

Authors:  Roberta Zupo; Fabio Castellana; Sara De Nucci; Annamaria Sila; Simona Aresta; Carola Buscemi; Cristiana Randazzo; Silvio Buscemi; Vincenzo Triggiani; Giovanni De Pergola; Claudia Cava; Madia Lozupone; Francesco Panza; Rodolfo Sardone
Journal:  Biomedicines       Date:  2022-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.